[1]
Gailite L, Valenzuela-Palomo A, Sanoguera-Miralles L, Rots D, Kreile M, Velasco EA. UGT1A1 Variants c.864+5G}T and c.996+2_996+5del of a Crigler-Najjar Patient Induce Aberrant Splicing in Minigene Assays. Frontiers in genetics. 2020:11():169. doi: 10.3389/fgene.2020.00169. Epub 2020 Mar 6
[PubMed PMID: 32211025]
[2]
Erps LT, Ritter JK, Hersh JH, Blossom D, Martin NC, Owens IS. Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro. The Journal of clinical investigation. 1994 Feb:93(2):564-70
[PubMed PMID: 7906695]
[3]
Kadakol A, Sappal BS, Ghosh SS, Lowenheim M, Chowdhury A, Chowdhury S, Santra A, Arias IM, Chowdhury JR, Chowdhury NR. Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus. Journal of medical genetics. 2001 Apr:38(4):244-9
[PubMed PMID: 11370628]
[4]
Collaud F, Bortolussi G, Guianvarc'h L, Aronson SJ, Bordet T, Veron P, Charles S, Vidal P, Sola MS, Rundwasser S, Dufour DG, Lacoste F, Luc C, Wittenberghe LV, Martin S, Le Bec C, Bosma PJ, Muro AF, Ronzitti G, Hebben M, Mingozzi F. Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. Molecular therapy. Methods & clinical development. 2019 Mar 15:12():157-174. doi: 10.1016/j.omtm.2018.12.011. Epub 2018 Dec 31
[PubMed PMID: 30705921]
[5]
Ebrahimi A, Rahim F. Crigler-Najjar Syndrome: Current Perspectives and the Application of Clinical Genetics. Endocrine, metabolic & immune disorders drug targets. 2018:18(3):201-211. doi: 10.2174/1871530318666171213153130. Epub
[PubMed PMID: 29237388]
Level 3 (low-level) evidence
[6]
Strauss KA, Ahlfors CE, Soltys K, Mazareigos GV, Young M, Bowser LE, Fox MD, Squires JE, McKiernan P, Brigatti KW, Puffenberger EG, Carson VJ, Vreman HJ. Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier. Hepatology (Baltimore, Md.). 2020 Jun:71(6):1923-1939. doi: 10.1002/hep.30959. Epub 2020 Feb 5
[PubMed PMID: 31553814]
[7]
Mitchell E, Ranganathan S, McKiernan P, Squires RH, Strauss K, Soltys K, Mazariegos G, Squires JE. Hepatic Parenchymal Injury in Crigler-Najjar Type I. Journal of pediatric gastroenterology and nutrition. 2018 Apr:66(4):588-594. doi: 10.1097/MPG.0000000000001843. Epub
[PubMed PMID: 29176474]
[8]
Fata CR, Gillis LA, Pacheco MC. Liver Fibrosis Associated With Crigler-Najjar Syndrome in a Compound Heterozygote: A Case Report. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society. 2017 Nov-Dec:20(6):522-525. doi: 10.1177/1093526617697059. Epub 2017 Mar 14
[PubMed PMID: 28590786]
Level 3 (low-level) evidence
[9]
Vohr BR, Karp D, O'Dea C, Darrow D, Coll CG, Lester BM, Brown L, Oh W, Cashore W. Behavioral changes correlated with brain-stem auditory evoked responses in term infants with moderate hyperbilirubinemia. The Journal of pediatrics. 1990 Aug:117(2 Pt 1):288-91
[PubMed PMID: 2380830]
[10]
Wisnowski JL, Panigrahy A, Painter MJ, Watchko JF. Magnetic Resonance Imaging Abnormalities in Advanced Acute Bilirubin Encephalopathy Highlight Dentato-Thalamo-Cortical Pathways. The Journal of pediatrics. 2016 Jul:174():260-3. doi: 10.1016/j.jpeds.2016.03.065. Epub 2016 Apr 22
[PubMed PMID: 27113379]
[11]
Wisnowski JL, Panigrahy A, Painter MJ, Watchko JF. Magnetic resonance imaging of bilirubin encephalopathy: current limitations and future promise. Seminars in perinatology. 2014 Nov:38(7):422-8. doi: 10.1053/j.semperi.2014.08.005. Epub 2014 Sep 27
[PubMed PMID: 25267277]
[12]
Tcaciuc E, Podurean M, Tcaciuc A. Management of Crigler-Najjar syndrome. Medicine and pharmacy reports. 2021 Aug:94(Suppl No 1):S64-S67. doi: 10.15386/mpr-2234. Epub 2021 Aug 10
[PubMed PMID: 34527915]
[13]
Arias IM, Gartner LM, Cohen M, Ezzer JB, Levi AJ. Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity. The American journal of medicine. 1969 Sep:47(3):395-409
[PubMed PMID: 4897277]
[14]
Razek AAKA, Taman SE, El Regal ME, Megahed A, Elzeny S, El Tantawi N. Diffusion Tensor Imaging of Microstructural Changes in the Gray and White Matter in Patients With Crigler-Najjar Syndrome Type I. Journal of computer assisted tomography. 2020 May/Jun:44(3):393-398. doi: 10.1097/RCT.0000000000001008. Epub
[PubMed PMID: 32217895]
[15]
van der Veere CN, Sinaasappel M, McDonagh AF, Rosenthal P, Labrune P, Odièvre M, Fevery J, Otte JB, McClean P, Bürk G, Masakowski V, Sperl W, Mowat AP, Vergani GM, Heller K, Wilson JP, Shepherd R, Jansen PL. Current therapy for Crigler-Najjar syndrome type 1: report of a world registry. Hepatology (Baltimore, Md.). 1996 Aug:24(2):311-5
[PubMed PMID: 8690398]
[16]
Lund HT, Jacobsen J. Influence of phototherapy on the biliary bilirubin excretion pattern in newborn infants with hyperbilirubinemia. The Journal of pediatrics. 1974 Aug:85(2):262-7
[PubMed PMID: 4842799]
[17]
Zhang XR, Zeng CM, Liu J. [Effect and safety of intensive phototherapy in treatment of neonatal hyperbilirubinemia]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. 2016 Mar:18(3):195-200
[PubMed PMID: 26975813]
[18]
Nishioka T, Hafkamp AM, Havinga R, vn Lierop PP, Velvis H, Verkade HJ. Orlistat treatment increases fecal bilirubin excretion and decreases plasma bilirubin concentrations in hyperbilirubinemic Gunn rats. The Journal of pediatrics. 2003 Sep:143(3):327-34
[PubMed PMID: 14517515]
[19]
Van der Veere CN, Jansen PL, Sinaasappel M, Van der Meer R, Van der Sijs H, Rammeloo JA, Goyens P, Van Nieuwkerk CM, Oude Elferink RP. Oral calcium phosphate: a new therapy for Crigler-Najjar disease? Gastroenterology. 1997 Feb:112(2):455-62
[PubMed PMID: 9024299]
[20]
Van Der Veere CN, Schoemaker B, Bakker C, Van Der Meer R, Jansen PL, Elferink RP. Influence of dietary calcium phosphate on the disposition of bilirubin in rats with unconjugated hyperbilirubinemia. Hepatology (Baltimore, Md.). 1996 Sep:24(3):620-6
[PubMed PMID: 8781334]
[21]
Sokal EM, Silva ES, Hermans D, Reding R, de Ville de Goyet J, Buts JP, Otte JB. Orthotopic liver transplantation for Crigler-Najjar type I disease in six children. Transplantation. 1995 Nov 27:60(10):1095-8
[PubMed PMID: 7482714]
[22]
Ambrosino G, Varotto S, Strom SC, Guariso G, Franchin E, Miotto D, Caenazzo L, Basso S, Carraro P, Valente ML, D'Amico D, Zancan L, D'Antiga L. Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell transplantation. 2005:14(2-3):151-7
[PubMed PMID: 15881424]
[23]
Fox IJ, Chowdhury JR, Kaufman SS, Goertzen TC, Chowdhury NR, Warkentin PI, Dorko K, Sauter BV, Strom SC. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. The New England journal of medicine. 1998 May 14:338(20):1422-6
[PubMed PMID: 9580649]
[24]
Valaes T, Petmezaki S, Henschke C, Drummond GS, Kappas A. Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin. Pediatrics. 1994 Jan:93(1):1-11
[PubMed PMID: 8265301]
[25]
Kappas A, Drummond GS, Henschke C, Valaes T. Direct comparison of Sn-mesoporphyrin, an inhibitor of bilirubin production, and phototherapy in controlling hyperbilirubinemia in term and near-term newborns. Pediatrics. 1995 Apr:95(4):468-74
[PubMed PMID: 7700742]
[26]
Holstein A, Bryan CS. Three consecutive pregnancies in a woman with Crigler-Najjar syndrome type II with good maternal and neonatal outcomes. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2011 Feb:43(2):170. doi: 10.1016/j.dld.2010.08.003. Epub 2010 Sep 16
[PubMed PMID: 20843754]
[27]
Passuello V, Puhl AG, Wirth S, Steiner E, Skala C, Koelbl H, Kohlschmidt N. Pregnancy outcome in maternal Crigler-Najjar syndrome type II: a case report and systematic review of the literature. Fetal diagnosis and therapy. 2009:26(3):121-6. doi: 10.1159/000238122. Epub 2009 Sep 11
[PubMed PMID: 19752526]
Level 1 (high-level) evidence
[28]
He J, Yu L, Zhang S. Jaundice and rectal bleeding in a young man. Gut. 2011 Jul:60(7):892, 936. doi: 10.1136/gut.2009.181149. Epub 2010 Jun 10
[PubMed PMID: 20542867]
[29]
Berry R, Han JY, Kardashian AA, LaRusso NF, Tabibian JH. Hemobilia: Etiology, diagnosis, and treatment(☆). Liver research. 2018 Dec:2(4):200-208. doi: 10.1016/j.livres.2018.09.007. Epub 2018 Sep 22
[PubMed PMID: 31308984]
[30]
deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, Kleiner DE, Bonkovsky HL, Drug-Induced Liver Injury Network (DILIN). Amoxicillin-Clavulanate-Induced Liver Injury. Digestive diseases and sciences. 2016 Aug:61(8):2406-2416. doi: 10.1007/s10620-016-4121-6. Epub 2016 Mar 22
[PubMed PMID: 27003146]
[31]
Björnsson ES. Drug-induced liver injury due to antibiotics. Scandinavian journal of gastroenterology. 2017 Jun-Jul:52(6-7):617-623. doi: 10.1080/00365521.2017.1291719. Epub 2017 Feb 20
[PubMed PMID: 28276834]
[32]
Suresh G, Lucey JF. Lack of deafness in Crigler-Najjar syndrome type 1: a patient survey. Pediatrics. 1997 Nov:100(5):E9
[PubMed PMID: 9347003]
Level 3 (low-level) evidence
[33]
Strauss KA, Robinson DL, Vreman HJ, Puffenberger EG, Hart G, Morton DH. Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. European journal of pediatrics. 2006 May:165(5):306-19
[PubMed PMID: 16435131]
[34]
Hamza A. Kernicterus. Autopsy & case reports. 2019 Jan-Mar:9(1):e2018057. doi: 10.4322/acr.2018.057. Epub 2019 Jan 14
[PubMed PMID: 30863731]
[35]
Barış Z, Özçay F, Usta Y, Özgün G. Liver Cirrhosis in a Patient with Crigler Najjar Syndrome. Fetal and pediatric pathology. 2018 Aug:37(4):301-306. doi: 10.1080/15513815.2018.1492053. Epub 2018 Sep 27
[PubMed PMID: 30260719]